News

  • All
  • Cardiovascular
  • Central Nervous System
  • Gastroenterology
  • Syncrosome News
NEW RATING SCALE OF AIMs IN OUR L-DOPA INDUCED DYSKINESIAS RAT MODEL

L-DOPA remains the most effective therapy in the management of the motor symptoms of Parkinson's disease (PD). However, chronic treatment with levodopa is associated with the risk of development of motor fluctuations such as choreic and dystonic abnormal and involuntary movements affecting mainly the upper...

Syncrosome & the 2nd Annual Neuroscience Conference.

As you know Syncrosome is a preclinical CRO managing efficacy in vivo/ in vitro studies with more than 15 disease models validated in house and reproducible. Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS disease...

SYNCROSOME: new website launched!

Syncrosome is just launching its new website. This is the result of the collaboration between Syncrosome’s internal team, consultants and customers: www.syncrosome.com. Thank you for your collaboration, and we hope you will find all information you are looking for! Please do not hesitate to visit it and...

Syncrosome hired a new colleague as Technical Manager for the lab

Syncrosome, a Preclinical CRO specialized in in vivo efficacy experiments, is pleased to welcome our new colleague, Caroline Babuleaud-Casano as our new Technical Manager. Caroline hold 2 MSc., 1 in Neurosciences and 1 in Neuro-pharmacology. During her 10 years professional experience, she has been working on various...

Immunization therapies, synuclein and Parkinson’s disease – multiple system atrophy

Vaccination is increasingly being investigated as a potential treatment for synucleinopathies, a group of neurodegenerative diseases including Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies associated with α-synuclein pathology. All lack a causal therapy. Development of novel, disease-altering treatment strategies is urgently needed....

Synucleopathies and preclinical Parkinson disease models

Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies, have all something in common. They all belong to a group of neurodegenerative diseases called synucleinopathies, including preclinical Parkinson, characterized by the abnormal accumulation of aggregates of α-synuclein protein in neurons, nerve fibres or glial...

Syncrosome hired a new colleague for its Cardiovascular dpt

Syncrosome, a  Preclinical CRO specialized in in vivo efficacy experiments, is pleased to welcome Dr Viviana Delgado Betancourt as our new Cardiovascular Study Director. Viviana brings to the table several years of experience acquired over the courseof her thesis/PhD that focused on cardioprotection against Ischemia-Reperfusion injury...

Poster PAH sugen – ERS meeting

Below a poster presented by Syncrosome during the last European Respiratory Society meeting showing interesting result concerning Pulmonary Arterial Hypertension induced on rats with Sugen with remodeling in small pulmonary arteries (PAH sugen). Results are reproducible and shows a vascular remodeling, increased Right Ventricular Systolic Pressure...

Syncrosome Poster 6 OHDA Parkinson and dyskinesia

This poster has been presented at the last 2015 World Parkinson Congress in France, and shows interesting results concerning an antidyskinetic compound in a rat 6 OHDA Parkinson model. Dyskinesias are induced by LDopa, and various parameters are assessed, biochemical and symptomatic. Microdialysis is used to evaluate...